Arcturus Therapeutics Holdings (ARCT) Accumulated Depreciation & Amortization (2018 - 2025)
Arcturus Therapeutics Holdings (ARCT) has disclosed Accumulated Depreciation & Amortization for 8 consecutive years, with $12.5 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 5.76% year-over-year to $12.5 million, compared with a TTM value of $12.5 million through Dec 2025, up 5.76%, and an annual FY2025 reading of $12.5 million, up 5.76% over the prior year.
- Accumulated Depreciation & Amortization was $12.5 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $13.4 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $13.4 million in Q2 2025 and bottomed at $3.4 million in Q1 2021.
- Average Accumulated Depreciation & Amortization over 5 years is $8.5 million, with a median of $9.0 million recorded in 2023.
- The sharpest move saw Accumulated Depreciation & Amortization soared 51.13% in 2023, then increased 5.76% in 2025.
- Year by year, Accumulated Depreciation & Amortization stood at $4.3 million in 2021, then skyrocketed by 35.88% to $5.8 million in 2022, then skyrocketed by 51.13% to $8.7 million in 2023, then surged by 35.14% to $11.8 million in 2024, then rose by 5.76% to $12.5 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for ARCT at $12.5 million in Q4 2025, $13.4 million in Q2 2025, and $11.8 million in Q4 2024.